Pharma news
Americas
Integrating AI into patent workflows promises efficiency gains, but requires strict oversight regarding accuracy, ethics, and data security. This panel explores the practical realities of deploying AI tools responsibly while maintaining the high standards required in life sciences prosecution. 31 May 2026
Americas
Is Brazil moving toward a more predictable patent system, or simply shifting risk? This session examines the far-reaching impact of the ADI 5529 ruling, analysing how the end of automatic patent term extensions is reshaping filing and enforcement strategies. 30 May 2026
Americas
The post-grant challenge landscape is intensifying on both sides of the Atlantic. This panel analyses recent developments in IPRs, PGRs, EPO oppositions, and the UPC, detailing strategies to simultaneously defend existing portfolios and clear competitive space. 29 May 2026
Europe
A European court dismissed a challenge by a German generics manufacturer, confirming the validity of a patent covering a blood cancer combination therapy. 28 May 2026
Americas
Choosing between patent protection and trade secrets is a delicate balancing act, especially amid regulatory scrutiny and unpredictable patent office timelines. This session delves into the frontlines of IP strategy, offering practical guidance on when each protection mechanism serves best. 28 May 2026
Asia
China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it. 27 May 2026
Careers
A senior pharmaceutical lawyer, with experience across private practice and Big Pharma, joins the company after a decade-long tenure at Teva. 27 May 2026
Americas
Structuring successful IP transactions in the life sciences sector requires rigorous due diligence and sophisticated valuation models. This panel brings together deal-makers and valuation experts to share strategies for protecting value and enabling innovation in complex M&A and licensing deals. 27 May 2026
Americas
Two days of discussions at LSPN North America revealed an industry grappling with narrower patent claims, global strategy changes, AI disruption and tougher dealmaking conditions. 26 May 2026
Europe
The EPO's approach to claim interpretation has shifted significantly following the G1/24 decision. This session unpacks how Technical Boards of Appeal are newly applying the mandate to consult descriptions and drawings, and what this means for drafting and opposition strategy. 26 May 2026